The role of body mass index at diagnosis in patients with inflammatory breast cancer.
AuteursBorremans K, Nguyen HL, De Schepper M, Lerebours F, Vion R, Clatot F, Berghian A, Maetens M, Isnaldi E, Molinelli C, Lambertini M, Grillo F, Zoppoli G, Dirix L, Punie K, Wildiers H, Smeets A, Nevelsteen I, Neven P, Vincent-Salomon A, Larsimont D, Duhem C, Viens P, Bertucci F, Biganzoli E, Vermeulen P, Floris G, Richard F, Desmedt C
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
AuteursMalorni L, Tyekucheva S, Gombos A, Hasler-Strub U, Zamagni C, Chakiba-Brugère C, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Ruepp B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L
Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM project.
AuteursHillen B, Oestreicher G, Schwab L, Enders K, Simon P, Elme A, Ben-Aharon I, Goshenlago T, Neuzillet C, Sclafani F, Beltran EEM, Schuster M, Doncheva H, Ruckes C, Karlecik M, Petrowski K, Rosenbaum D, Diou C, Ballas A, Vlachostergiou A, Mastricci D, Scherrer A, Pilz M, Flechsig J, Apostolidis L, Krooupa AM, Chintha S, Musisi IW, Tzavara NP, Kakasis A, Hadjikypri X, Karra S, Chatzipanagiotou K, Drivas I, Dacasa H, Moehler M
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
AuteursMoreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.
AuteursKwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M, Feifer A, Lajkosz K, Wettstein MS, Chan A, Lee T, Nguyen M, Kassouf W, Black PC, Breau RH, Lodde M, Fairey A, Lattouf JB, Jeldres C, Rendon R, Alimohamed N, Fleshner NE, Diamand R, Gontero P, Sylvester RJ, van Rhijn BWG, Kamat AM, Johnson AEW, Zlotta AR, Kulkarni GS
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.
AuteursJacobs F, D'Amico S, Ferraro E, Agostinetto E, Tondini C, Gaudio M, Benvenuti C, Gerosa R, Saltalamacchia G, Zazzetti E, Di Rienzo R, Buonaiuto R, Martorana F, Chirco A, De Sanctis R, Della Porta MG, Santoro A, Vigneri P, Arpino MG, Giuliano M, Fornier M, de Azambuja E, Zambelli A
